NEWS | BEAM Alliance


XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

July 16, 2020 at 4:04 PM EDT

XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.

DUBLIN, Ireland, July 16, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults. Additional information on the Notice of Compliance from Health Canada dated July 10, 2020 is available at

Full PR available here